TY - JOUR
T1 - A Novel Imaging Marker for Small Vessel Disease Based on Skeletonization of White Matter Tracts and Diffusion Histograms
AU - Baykara, Ebru
AU - Gesierich, Benno
AU - Adam, Ruth
AU - Tuladhar, Anil Man
AU - Biesbroek, J. Matthijs
AU - Koek, Huiberdina L.
AU - Ropele, Stefan
AU - Jouvent, Eric
AU - Chabriat, Hugues
AU - Ertl-Wagner, Birgit
AU - Ewers, Michael
AU - Schmidt, Reinhold
AU - de Leeuw, Frank Erik
AU - Biessels, Geert Jan
AU - Dichgans, Martin
AU - Duering, Marco
N1 - © 2016 American Neurological Association.
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Objective: To establish a fully automated, robust imaging marker for cerebral small vessel disease (SVD) and related cognitive impairment that is easy to implement, reflects disease burden, and is strongly associated with processing speed, the predominantly affected cognitive domain in SVD. Methods: We developed a novel magnetic resonance imaging marker based on diffusion tensor imaging, skeletonization of white matter tracts, and histogram analysis. The marker (peak width of skeletonized mean diffusivity [PSMD]) was assessed along with conventional SVD imaging markers. We first evaluated associations with processing speed in patients with genetically defined SVD (n = 113). Next, we validated our findings in independent samples of inherited SVD (n = 57), sporadic SVD (n = 444), and memory clinic patients with SVD (n = 105). The new marker was further applied to healthy controls (n = 241) and to patients with Alzheimer's disease (n = 153). We further conducted a longitudinal analysis and interscanner reproducibility study. Results: PSMD was associated with processing speed in all study samples with SVD (p-values between 2.8 × 10-3 and 1.8 × 10-10). PSMD explained most of the variance in processing speed (R2 ranging from 8.8% to 46%) and consistently outperformed conventional imaging markers (white matter hyperintensity volume, lacune volume, and brain volume) in multiple regression analyses. Increases in PSMD were linked to vascular but not to neurodegenerative disease. In longitudinal analysis, PSMD captured SVD progression better than other imaging markers. Interpretation: PSMD is a new, fully automated, and robust imaging marker for SVD. PSMD can easily be applied to large samples and may be of great utility for both research studies and clinical use.
AB - Objective: To establish a fully automated, robust imaging marker for cerebral small vessel disease (SVD) and related cognitive impairment that is easy to implement, reflects disease burden, and is strongly associated with processing speed, the predominantly affected cognitive domain in SVD. Methods: We developed a novel magnetic resonance imaging marker based on diffusion tensor imaging, skeletonization of white matter tracts, and histogram analysis. The marker (peak width of skeletonized mean diffusivity [PSMD]) was assessed along with conventional SVD imaging markers. We first evaluated associations with processing speed in patients with genetically defined SVD (n = 113). Next, we validated our findings in independent samples of inherited SVD (n = 57), sporadic SVD (n = 444), and memory clinic patients with SVD (n = 105). The new marker was further applied to healthy controls (n = 241) and to patients with Alzheimer's disease (n = 153). We further conducted a longitudinal analysis and interscanner reproducibility study. Results: PSMD was associated with processing speed in all study samples with SVD (p-values between 2.8 × 10-3 and 1.8 × 10-10). PSMD explained most of the variance in processing speed (R2 ranging from 8.8% to 46%) and consistently outperformed conventional imaging markers (white matter hyperintensity volume, lacune volume, and brain volume) in multiple regression analyses. Increases in PSMD were linked to vascular but not to neurodegenerative disease. In longitudinal analysis, PSMD captured SVD progression better than other imaging markers. Interpretation: PSMD is a new, fully automated, and robust imaging marker for SVD. PSMD can easily be applied to large samples and may be of great utility for both research studies and clinical use.
UR - http://www.scopus.com/inward/record.url?scp=84983652653&partnerID=8YFLogxK
U2 - 10.1002/ana.24758
DO - 10.1002/ana.24758
M3 - Article
C2 - 27518166
SN - 0364-5134
VL - 80
SP - 581
EP - 592
JO - Annals of Neurology
JF - Annals of Neurology
IS - 4
ER -